0001415889-21-005966.txt : 20211215
0001415889-21-005966.hdr.sgml : 20211215
20211215183208
ACCESSION NUMBER: 0001415889-21-005966
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211213
FILED AS OF DATE: 20211215
DATE AS OF CHANGE: 20211215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CAPEK JOHN M
CENTRAL INDEX KEY: 0001328034
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-02189
FILM NUMBER: 211495358
MAIL ADDRESS:
STREET 1: 111 MONUMENT CIRCLE, SUITE 2900
CITY: INDIANAPOLIS
STATE: IN
ZIP: 46204-5129
FORMER NAME:
FORMER CONFORMED NAME: Capek John M
DATE OF NAME CHANGE: 20050523
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ABBOTT LABORATORIES
CENTRAL INDEX KEY: 0000001800
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 360698440
STATE OF INCORPORATION: IL
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 ABBOTT PARK ROAD
CITY: ABBOTT PARK
STATE: IL
ZIP: 60064-3500
BUSINESS PHONE: 2246676100
MAIL ADDRESS:
STREET 1: 100 ABBOTT PARK ROAD
CITY: ABBOTT PARK
STATE: IL
ZIP: 60064-3500
4
1
form4-12152021_031259.xml
X0306
4
2021-12-13
0000001800
ABBOTT LABORATORIES
ABT
0001328034
CAPEK JOHN M
100 ABBOTT PARK ROAD
ABBOTT PARK
IL
60064
false
true
false
false
EXECUTIVE VICE PRESIDENT
Common shares without par value
2021-12-13
4
M
0
149600
34.94
A
470998
D
Common shares without par value
2021-12-13
4
S
0
149600
135.0515
D
321398
D
Option (right to buy)
34.94
2021-12-13
4
M
0
149600
0
D
2016-02-15
2023-02-14
Common Shares
149600
0
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.295 inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).
/s/ John M. Capek by Jessica H. Paik, Attorney-in-Fact
2021-12-15